ArticleCancer medicine2025
ROS1 Expression Correlates With Inguinal Lymph Node Affection in Vulvar Cancer Patients: A Retrospective Study.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ROS1 Expression Correlates With Inguinal Lymph Node Affection in Vulvar Cancer Patients: A Retrospective Study.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSystemic treatment options for vulvar squamous cell carcinoma (VSCC) are limited. ROS1, a tyrosine kinase implicated, for example, in non-small cell lung cancer (NSCLC), has recently shown responsiveness to tyrosine kinase inhibitors. This study investigated immunohistochemical ROS1 expression in VSCC to explore its potential as a future therapeutic target in this rare malignancy.
methodsIn this retrospective study, 48 patients with VSCC undergoing vulvectomy were included. Clinicopathological data were collected in a standardized manner. Immunohistochemistry (IHC) was used to assess ROS1 expression on an ordinal scale from 0 (absent staining) to 3 (> 50% of neoplastic cells demonstrated cytoplasmatic staining); levels 0 and 1 were considered negative, while 2 and 3 were rated as positive. After differences and correlations with clinicopathological parameters were evaluated between positive and negative tumors, we fitted logistic regression and survival models to assess the association of ROS1 with inguinal lymph node involvement and overall survival. Statistical analysis was conducted using GraphPad and Jamovi.
resultsROS1 IHC levels were associated with lymph node involvement [odds ratio (OR) 2.396, 95% confidence interval (CI) 1.034-5.555, logistic regression, p = 0.042]. ROS1 positive tumors demonstrated no difference in overall survival compared with negative ones [hazards ratio (HR) 0.837, 95% CI 0.283-2.479, log-rank (Mantel-Cox) test, p = 0.738].
conclusionROS1 expression was associated with inguinal lymph node involvement but not overall survival among VSCC patients. Further studies are required to elucidate the role of ROS1 in VSCC therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.